Connect Biopharma Holdings (CNTB) FCF Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported FCF Margin for 3 consecutive years, with 9469.23% the latest figure, recorded in Q1 2026.

• Quarterly FCF Margin changed N/A year-over-year to 9469.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24795.71% (changed N/A YoY) and the FY2025 annual result came in at 80954.69%, down 8086111.0% from the prior year.
• FCF Margin grew to 9469.23% in Q1 2026 per CNTB's latest filing, from 109000.0% in the prior quarter.
• Over the last five years, FCF Margin for CNTB reached as high as 377.08% in Q4 2024 and fell as low as 109000.0% in Q3 2025.
• A 3-year average of 29357.58% and a median of 9469.23% in 2026 frame the typical range for FCF Margin.
• The largest YoY upside for FCF Margin was 10792092 bps in 2025 against a maximum downside of 10792092 bps in 2025.
• Year by year, FCF Margin stood at 377.08% in 2024, then slumped by 28807 bps to 109000.0% in 2025, then surged by 91 bps to 9469.23% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 9469.23%, 109000.0%, and 26862.5% for Q1 2026, Q3 2025, and Q2 2025 respectively.